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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.013The molecular mechanisms involved in human cellular susceptibility to prion infection remain poorly
deﬁned. This is due, in part, to the absence of any well characterized and relevant cultured human cells
susceptible to infection with human prions, such as those involved in Creutzfeldt-Jakob disease. In
variant Creutzfeldt-Jakob disease, prion replication is thought to occur ﬁrst in the lymphoreticular system
and then spread into the brain. We have, therefore, examined the susceptibility of a human tonsil-derived
follicular dendritic cell-like cell line (HK) to prion infection. HK cells were found to display a readily
detectable, time-dependent increase in cell-associated abnormal prion protein (PrPTSE) when exposed to
medium spiked with Creutzfeldt-Jakob disease brain homogenate, resulting in a coarse granular peri-
nuclear PrPTSE staining pattern. Despite their high level of cellular prion protein expression, HK cells failed
to support infection, as judged by longer termmaintenance of PrPTSE accumulation. Colocalization studies
revealed that exposure of HK cells to brain homogenate resulted in increased numbers of detectable
lysosomes and that these structures immunostained intensely for PrPTSE after exposure to Creutzfeldt-
Jakob disease brain homogenate. Our data suggest that human follicular dendritic-like cells and
perhaps other human cell types are able to avoid prion infection by efﬁcient lysosomal degradation of
PrPTSE. (Am J Pathol 2014, 184: 64e70; http://dx.doi.org/10.1016/j.ajpath.2013.09.013)Supported in part by anMedical Research Council Ph.D. studentship from
theUniversity of Edinburgh,Centre forClinical BrainSciences (Z.K.), a grant
from the Chief’s Scientist’s Ofﬁce of the Scottish Government (CZB/4/588)
(M.W.H and P.D.S.). The National Creutzfeldt-Jakob Disease Research &
SurveillanceUnit is funded by theDepartment ofHealthUnitedKingdomand
the Scottish Government, and the Edinburgh Brain Bank is supported by the
Medical Research Council (MRC G0900580).
This is an independent report and the views expressed in the publication are
those of the authors and not necessarily those of the Department of Health,
United Kingdom.
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Disclosure: P.D.-S. is Chief Scientiﬁc Ofﬁcer of Roslin Cells.Variant Creutzfeldt-Jakob disease (vCJD) is a fatal neurode-
generative disease resulting from oral infection with the
bovine spongiform encephalopathy (BSE) agent.1 BSE and
vCJD belong to a group of transmissible spongiform en-
cephalopathies (TSE) in which the infectious agent or prion is
believed to be a conformationally altered and aggregated form
prion protein TSE (PrPTSE) of the host-encoded cellular prion
protein (PrPC), replicated by a templated conformational
conversion process that resembles seeded aggregation.2 vCJD
involves the lymphoreticular system, probably before neu-
roinvasion and the subsequent appearance of neurological
symptoms.3,4 Accumulation of PrPTSE in the follicular den-
dritic cells (FDCs) residing in the germinal centers in the
tonsil, spleen, appendix, and lymph node is a consistent
feature of vCJD pathology.5,6 Exposure of the United
Kingdom population to BSE is thought to have been wide-
spread and yet the resultant vCJD epidemic has thus far beenstigative Pathology.
.limited to 177 cases [National CJD Research & Surveillance
Unit (NCJDRSU), http://www.cjd.ed.ac.uk/documents/ﬁgs.
pdf, last accessed August 30, 2013]. All clinical cases of
deﬁnite vCJD that have been tested are of the prion protein
gene PRNP codon 129MM genotype (NCJDRSU, http://www.
Lysosomal Degradation of Abnormal PrPcjd.ed.ac.uk/documents/report20.pdf, last accessed August 30,
2013). However, studies based on PrPTSE immunostaining of
routine appendectomy, tonsillectomy, and autopsy tissues
indicate that the prevalence of infection in the United Kingdom
is higher than the incidence of clinical vCJD would seem to
suggest and indicates that all three possible PRNP codon 129
genotypes (MM,MV, VV) are susceptible to infection with the
vCJD/BSE agent.7e11 [Summary results of the second na-
tional survey of abnormal prion prevalence in archived ap-
pendix specimens are available online (Health Protection
Report, http://www.hpa.org.uk/hpr/archives/2012/news3212.
htm#bnrmlprn, last accessed August 30, 2013)]. The mecha-
nismbywhich cells interactwith prions is only beginning to be
deﬁned.12 Despite a wealth of data showing that cultured cells
of a variety of species and phenotypes can propagate animal
prions, evidence that cultured human cells have been infected
with human prion agents is restricted to a single unconﬁrmed
report from 1995. In this report, Ladogana et al13 described
infection of the human neuroblastoma SH-SY5Y cell line
(PRNP codon 129 genotype MM) with a brain homogenate
from a sporadic CJD patient (also PRNP codon 129 genotype
MM). However, the infection proved to be unstable13 and this
initial success in infecting human cells with the CJD agent has
not been capitalized on. Interestingly, RK13 rabbit kidney
epithelial cells expressing human PrP were found to be resis-
tant to prion infection when exposed directly to sporadic CJD
prions.14
Our previous investigations of human embryonic stem
cells (hESC) showed extensive and rapid uptake and clear-
ance of PrPTSE present in crude homogenates of bovine and
human prion disease brain tissue added directly to culture
medium.14 Uptake and clearance in these hESC did not
appear to depend on the species, form of CJD (sporadic or
variant), or the PRNP codon 129 genotype of the inoculum or
the hESC, suggesting involvement of general rather than
speciﬁc uptake mechanisms.15 This is consistent with earlier
observations made using rodent adapted scrapie prions and
rodent cell lines.16 Considering the involvement of the lym-
phoreticular system in vCJD, we chose to investigate the
mechanisms involved in human cellular susceptibility to
prion infection and PrPTSE intracellular fate using the human
cell line HK, which is derived from human tonsillectomy
tissue and shares features with FDCs.17 Our results demon-
strate that the human FDC-like HK cells, as far as we can
determine, are resistant to prion infection in vitro and that the
endosome/lysosome compartments are the likely sites of
PrPTSE intracellular trafﬁcking and degradation.
Materials and Methods
Cell Culture
The HK cell line [a gift from Dr. Yong Sung Choi (Alton
Ochsner Medical Foundation, New Orleans, LA)] was isolated
fromhuman tonsils and cultivated as previously described.17 For
studies involving confocalmicroscopy, cellswere detachedwithThe American Journal of Pathology - ajp.amjpathol.org0.05%Trypsin-EDTA(Invitrogen,Paisley,UK) andplated onto
pre-coated glass chamber slides (Nunc Lab-TekII CC2, Fisher
Scientiﬁc, Loughborough, UK) 1 day before exposure.
Brain Tissue
Brain tissue from autopsy-proven, well-characterized cases of
deﬁnite vCJD, iatrogenic CJD (iCJD) associated with human
growth hormone therapy, Alzheimer disease (each with con-
sent for use in research), and cattle BSE were selected for the
study. The details are summarized in Supplemental Table S1.
All human tissues were obtained from the Edinburgh Brain
Bank (LREC 2000/4/157) and were handled exclusively in a
category 3 biosafety containment facility according to strin-
gent health and safety protocols. The cattle BSE brain tissue
was generously provided by the Animal Health Veterinary
LaboratoryAgencyTSEArchive (Weybridge,UK).Detection
of PrPTSE in prion disease brain homogenates was conﬁrmed
by proteinase K (PK; VWR International, Lutterworth, UK)
digestion, and immunoblot analysis as previously described.18
PRNP Codon 129 Genotyping
HK cells had their PRNP codon 129 genotype determined as
previously described.14
Brain Spiked Medium
For all experiments described in this article, brain tissues were
homogenized (10% w/v) at 4C in PBS (Invitrogen) con-
taining 5% glucose (Fisher Scientiﬁc) and cleared by centri-
fugation at 424.16 g for 5 minutes at 4C, then disrupted by
sonication (Sonicator model 3000; Misonix, Farmingdale,
NY) at 300W for 1minute, and diluted into culturingmedium
to a ﬁnal concentration of 1%. Other preparative methods
used in the challenge experiments were as described in
Supplemental Tables S2, S3, S4, S5, S6, S7, and S8.
HK Cell Challenges
HK cells were routinely cultured in Corning T25 cell culture
ﬂasks (Fisher Scientiﬁc) and after reaching 50% to 60%
conﬂuence they were exposed to brain-spiked media, which
was prepared according to the methodological variations
summarized in Supplemental Tables S2, S3, S4, S5, S6, S7,
and S8. Every challenge was performed in duplicate and one
ﬂask was used for further subcultivation, whereas the other
ﬂaskwas used to prepare a cell lysate for immunoblot analysis.
Immunoblot Analysis
Exposed cells were washed twice with PBS at 4C, then lyzed
for 15 minutes on ice with extraction buffer (0.5% NP-40,
0.5% sodium deoxycholate, PBS-T pH 7.4), and collected
using a cell scraper into a safe-lock tube. The samples were
then digestedwith proteinaseK at a concentration of 50mg/mL
at 37C for 60 minutes and digestion was terminated with 165
Krejciova et almmol/L Pefablock SC (Roche, West Sussex, UK). Samples
were centrifuged at 20817.16 g for 60minutes at 4Cand the
pellets analyzed by immunoblot as previously described.6,18,19
Immunoﬂuorescence
Immunoﬂuorescence on the cells exposed to 1% (w/v) brain
homogenate for speciﬁed time periods was performed
as previously described.14 Brieﬂy, cells were extensively
washed with PBS, ﬁxed with 4% paraformaldehyde (Sigma-
Aldrich, Dorset, UK), and permeabilized with 0.1% Triton X-
100 (Sigma-Aldrich) in PBS. If proteinase K pretreatment was
included, then the cells were incubated with 0.3 mg/mL for 9
minutes at 37C and digestion was stopped with 1 mmol/L
Pefabloc SC for 5 minutes at room temperature. The cells
were then washed with PBS and blocked with 3% bovine
serum albumin (BSA; Invitrogen) in Dulbecco’s phosphate
buffered saline (DPBS; Invitrogen) and incubated with
antieprion protein monoclonal antibody 6H4 (Prionics,
Schlieren-Zurich, Switzerland) or 8H4.20 In some experi-
ments, the cells were incubated with antibodies to late
endosomal/lysosomal-speciﬁc proteins Lamp1 or Lamp2b
(Abcam, Cambridge, UK) or glial ﬁbrillary acidic protein
(GFAP; Dako, Ely, UK). Then the cells were washed and
incubated with the ﬂuorescein isothiocyanate secondary
antibody, Alexa 488 (Invitrogen) labeling the PrP and Alexa
546 (Invitrogen) revealing late endosomes/lysosomes or
GFAP. The nuclei were counterstained with DAPI (Invi-
trogen). Slides were mounted with Vectashield (Vector Lab-
oratories Ltd., Peterborough, UK) and examined by confocal
microscopy.
Confocal Microscopy, Particle-Based Colocalization,
and Statistical Data Analysis
Immunostained cultures were examined by laser scanning
confocal microscope NIKON Eclipse TE2000-U with a
40  0.75 Plan Fluor DIC M/N2 dry and 60  1.40 Plan
Apo VC oil objectives. Images were exported via EZ-C1
software Gold version 3.30 and analyzed using ImageJ
version 1.45s (NIH, Bethesda, MD). Z-stacks were acquired
with Z-steps of 0.25 mm. Colocalization was assessed using
the particle-based approach21 using ImageJ plugin JACoP.
Manders’ colocalization coefﬁcient22 was then calculated
and values were plotted on a graph using Microsoft Ofﬁce
Excel (Redmond, WA).
Results
Human FDC-Like HK Cells Are Resistant to Infection
with Human Prions in Vitro
The HK cells were found to express readily detectable levels
of PrPC as judged by Western blot analysis (Figure 1A).
Direct immunoblot comparison showed the PrPC level to be
equivalent to or greater than that found in the normal human66brain reference standard (NHB20/0005) obtained from the
National Institute for Biological Standards and Control TSE
Resource Centre23 (data not shown). The PRNP codon 129
genotype of the HK cell line used was found to be of VV.
Uptake of exogenous PrPTSE was found to be rapid and the
amount of HK cell-associated PrPTSE increased steeply with
time of exposure to vCJD brain-spiked medium (Figure 1B).
Dual immunolabeling for PrPTSE and GFAP (Figure 1C)
showed that both proteins accumulated in the cytosol in a
partially overlapping pattern. Uptake, therefore, did not
appear to be PrP-speciﬁc, rather it suggested a nonspeciﬁc
uptake of complex brain homogenate components. Confocal
microscopy Z-stack sections conﬁrmed the intracellular
localization of PrPTSE and showed a coarse granular peri-
nuclear appearance of the intracellular PrPTSE (Figure 1D).
HK cell cultures were tested for their ability to support a
prion infection by exposure to crude homogenates of CJD
brain (including vCJD MM and iatrogenic CJD of the VV
andMV genotypes) and BSE brain (Supplemental Table S1),
followed by assessment of cellular PrPTSE by Western blot
analysis and immunocytochemistry. A wide variety of
inocula preparations and exposure protocols were used
based on the previously successful infection of other cell
types (Supplemental Tables S2, S3, S4, S5, S6, S7, and
S8).12,24e34 No conditions were found that established a
stable prion infection in HK cells, as judged by the failure
of HK cell cultures to maintain PrPTSE levels in the days to
weeks after exposure to CJD brain inoculum. An example
of an immunoblot of HK cells exposed to iCJD brain
inoculum with a PRNP codon 129 genotype matching that
of the HK cells (VV genotype) and analyzed at speciﬁc time
points is shown in Figure 1, E and F. This showed increased
cell-associated PrPTSE initially, but the signal gradually
diminished over time when the cells were grown in fresh
(unspiked) medium. After the ﬁrst passage, the cell-
associated PrPTSE could no longer be detected in the cell
lysate (Figure 1E). In case cellular infection was a very rare
event, requiring time to become established and spread
throughout the culture, we continued to culture the cells
until they were senescent (>170 days). However, PrPTSE
could not be detected in these aged cultures by immunoblot
analysis (Figure 1F). Immunocytochemical analysis of the
HK cells exposed to iCJD was carried up to the third pas-
sage postexposure. No evidence of residual PrPTSE was
found (data not shown). If residual (or newly formed)
PrPTSE was present in these cultures, it was at levels below
those detectable by Western blot analysis and immunocy-
tochemistry. Therefore, despite being cells with a pheno-
type similar to those susceptible to BSE infection in vivo,
HK cells appeared resistant to infection in vitro, even when
there was no species barrier (exposure to vCJD brain ho-
mogenate) or when the PRNP codon 129 genotype was
matched (exposure to iCJD VV2 brain homogenate).
Therefore, we decided to investigate the fate of the exoge-
nous PrPTSE taken up by HK cells exposed to the vCJD
inoculum.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 A: PrPC in HK cells was analyzed by immunoblot analysis using antiePrP mAb 3F4. B: The time-dependent uptake of PrPTSE (mAb 6H4) by HK cells
exposed to vCJD brain homogenate. C: Uptake of PrPTSE (mAb 6H4, green) and GFAP (red) by HK cells demonstrated by immunoﬂuorescence of cells exposed to vCJD
and Alzheimer disease (AD) brain homogenate for 48 hours. Nuclei were counterstained with DAPI (blue). D: Immunoﬂuorescence analysis of the intracellular
accumulationof the exogenousPrPTSE inHK cells exposed to vCJD for 24hours by Z-stack analysis (optical sectioning), allowing visualizationof different levels of the
immunostained cell with the bottom Z-stack, middle Z-stack, and top Z-stack. PrP mAb 8H4 (green). Nuclei were counterstained with DAPI (blue). E: Immunoblot
analysis of the uptake and clearance of PrPTSE fromHK cells exposed to iCJD brain-spikedmedium (inoculum iCJD) for indicated times, followed by indicated recovery
times (up to 120hours). Subsequently the cells were split at a ratio of 1:2 and grown until conﬂuence at which time point theywere also analyzed. The antiePrPmAb
used was 6H4. F: Immunoblot analysis showing the uptake and clearance of PrPTSE fromHK cells and their failure to support prion propagation. Cells were exposed to
iCJD1 brain-spiked medium for 48 hours and then cultured in fresh medium and passaged until senescence (177 days post challenge, at passage 19). Samples were
taken for immunoblot analysis at the stated number of hours (h) of exposure and at subsequent stated days (d) postexposure. The passage number (p) is also given.
The antiePrP mAb used was 6H4. The molecular mass in the immunoblots (A, B, E, and F) is marked in kDa (left) on each blot. Scale bars: 20 mm (C and D).
Lysosomal Degradation of Abnormal PrPLate Endosomes/Lysosomes Are a Destination of
Exogenous PrPTSE in HK Cells
The intracellular fate and the subcellular site of the endo-
cytosed exogenous PrPTSE was investigated after vCJD
brain homogenate exposure using immunohistochemistry
to colocalize PrPTSE with a range of markers of different
cellular compartments including endoplasmic reticulum,
golgi apparatus, early endosome, and recycling endosomes.
Only in the case of the late endosomal/lysosomal compart-
ment was there clear evidence of colocalization found
(Figure 2A). The cells were immunolabeled for PrP [mono-
clonal antibody (mAb) 6H4] and lysosomes (mAb against
Lamp2b). A time-dependent increase of cell-associated
PrPTSE was clearly observed and an apparent colocalization
was seen in the merged channels. Almost all visible Lamp2b-
labeled structures were positive for exogenous PrPTSE at 48
and 72 hours postexposure. The observation was conﬁrmedThe American Journal of Pathology - ajp.amjpathol.orgusing an antibody against Lamp1 (data not shown). However,
the PrPTSE localizing with markers of lysosomes only rep-
resents a small proportion of detectable intracellular PrPTSE.
The exogenous PrPTSE colocalization with lysosomes was
assessed statistically using a particle-based colocalization
method (Figure 2B). The graph conﬁrms an increasing trend
of PrPTSE positive lysosomes with time of exposure. The data
are representative of seven independent, but nonidentical
experiments. We also found that the number of Lamp2b-
positive structures within the cell increased with time of
exposure and that this was a general response to exposure to
brain homogenate, occurring after exposure to Alzheimer
disease, as well as vCJD brain homogenate (Figure 2C).
Discussion
The known involvement of FDCs in vCJD and the high
levels of PrPC expressed by FDC-like HK cells suggested67
Figure 2 A: Images illustrating the time-dependent colocalization of exog-
enous PrPTSE (mAb 6H4, green) within lysosomes (mAb to Lamp2b, red) during
exposure of HK cells to vCJD brain homogenate. The yellow color in the merged
channels indicates colocalization (insets, white arrows). Nuclei were counter-
stained with DAPI (blue). B: Quantitation of the preferential colocalization of
exogenous PrPTSE with lysosomes (Lamp2b) in HK cells after exposure to vCJD
brain homogenate. Values were calculated by applying Manders’ colocalization
coefﬁcient to an immunoﬂuorescence data set. Error bars indicate SEM. C: The
number of lysosomes (Lamp2b-positive vesicles, white arrows) increased both in
cells exposed to vCJD brain homogenate and in cells exposed to Alzheimer disease
(AD) brain homogenate as compared to unexposed cells. PrP mAb 6H4 (green).
Lamp2b mAb (red). Colocalization (yellow). Nuclei were counterstained with DAPI
(blue). Scale bars: 20 mm (A and C). h, hours; PK, proteinase K.
Krejciova et althat these cells might be susceptible to prion infection and
competent to propagate the infection in vitro. We tested this
hypothesis directly by challenging HK cells with prion
disease brain homogenates. Despite using a wide variety of
inocula types (BSE, vCJD, and iCJD) and different prepa-
ration and exposure protocols in our attempts to infect HK
cells with prions, no condition could be found in which cell-
associated PrPTSE was maintained, even when the PRNP
codon 129 genotype of the cells and the inoculum was
matched and without species barrier (iCJD VV). This led us
to conclude that HK cells are either not competent to sup-
port prion replication or that HK cells, similar to hESC,
have mechanisms that allow for the uptake, but also efﬁcient
mechanisms to effect clearance of exogenous PrPTSE.
Dual immunolabeling for PrPTSE and GFAP indicated that
the uptake of material from brain homogenate is likely via a68general rather than a PrP-speciﬁc uptake mechanism. Judging
by the increase and subsequent loss of cell-associated PrPTSE
from the cultures exposed to prion disease brain-spiked me-
dium, it appears that PrPTSE is most likely actively internalized
and then either degraded or excreted by the cells. The intra-
cellular fate of the endocytosed exogenous PrPTSE was inves-
tigated after exposure to vCJD brain homogenate and this
showed that exogenous PrPTSE was being trafﬁcked to the late
endosomal/lysosomal compartment. The combination of i) an
increased number of lysosomes in these cells in response to
exposure to brain homogenate, ii) a proportion of PrPTSE
localizing to this compartment, and iii) the subsequent loss of
PrPTSE from these cells is strongly suggestive of lysosomal
degradation of PrPTSE. Deﬁnitive demonstration of a role for
lysosomal degradation of PrPTSE would require inhibition of
lysosomal function, nor on the basis of this current data can weajp.amjpathol.org - The American Journal of Pathology
Lysosomal Degradation of Abnormal PrPexclude the involvement of other systems inprocessingPrPTSE,
however, the data we show here are entirely consistent with
previous studies implicating lysosomal proteases in PrPTSE
degradation in rodent cells.35e41 Our observation is also in
agreement with a very recent report showing that in rodent cell
cultures with a stimulated autophagic pathway, ﬂuorescently
labeled PrPTSE is not processed via autophagy, but rather it is
directly targeted for degradation to lysosomes.42
In summary, to our knowledge this is the ﬁrst report of the
fate of PrPTSE from a naturally infectious human inoculum in
a physiologically relevant human cell line. Internalization
of misfolded PrP and its subsequent degradation in the
lysosomal compartment might function as a self-protective
cellular mechanism, serving to eliminate non-native, pre-
sumably dysfunctional, and potentially dangerous PrP
conformers, whether generated endogenously or acquired
through exposure to exogenous prion infectivity. The efﬁ-
cient degradation of exogenous PrPTSE shown here appears
to be at variance with the hypothesis previously advanced
that the late endosome/lysosome compartment is the site of
PrPC to PrPTSE conversion and that lysosomes function as the
bioreactor of PrPTSE formation during scrapie pathogen-
esis.43,44 The efﬁcient uptake and clearance of PrPTSE by HK
cells after acute exposure in vitro also contrasts markedly
with the accumulation of PrPTSE in FDCs in vCJD patients.
These differences might be attributed to the postmitotic status
of FDC in situ or they may be taken to indicate that HK cells
share some, but not all phenotypic traits of FDCs. The deri-
vation of FDCs, neurons, and glia from human embryonic or
human-induced pluripotent cell lines of deﬁned PRNP codon
129 genotype will allow the investigation of the balance of
prion uptake, replication, and/or degradation in cells more
closely resembling their in vivo counterparts.
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